# Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer

> **NCT01012817** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 88 (actual)

## Conditions studied

- Metastatic Malignant Solid Neoplasm
- Recurrent Fallopian Tube Carcinoma
- Recurrent Ovarian Carcinoma
- Recurrent Primary Peritoneal Carcinoma
- Unresectable Solid Neoplasm

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacogenomic Study
- **OTHER:** Pharmacological Study
- **DRUG:** Topotecan Hydrochloride
- **DRUG:** Veliparib

## Key facts

- **NCT ID:** NCT01012817
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2009-11-03
- **Primary completion:** 2019-01-13
- **Final completion:** 2027-03-10
- **Target enrollment:** 88 (ACTUAL)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01012817

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01012817, "Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01012817. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*